Trastuzumab emtansine for treating HER2-positive, unresectable locally advanced or metastatic breast cancer after treatment with trastuzumab and a taxane

  • Technology appraisal guidance
  • TA371
  • Published: 

This guidance has been updated and replaced by NICE technology appraisal guidance 458.